EUVIMEDEUVIMED entdecken
Systematische ÜbersichtLeitlinie

A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults

Mohamed O Seisa iD, Tarek Nayfeh iD, Bashar Hasan, Mohammed Firwana, Samer Saadi, Ahmed Mushannen, Sahrish H Shah, Noora S Rajjoub, Magdoleen H Farah, Larry J Prokop, Zhen Wang, Ghada El-Hajj Fuleihan und 2 weitere

The Journal of Clinical Endocrinology & Metabolism · 15.02.2023 · 108 (3) · 585-591

DOI: 10.1210/clinem/dgac631 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 21.12.2022. Verfasst von Mohamed O Seisa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic Evidence-Based Practice Center, Rochester, MN 55902, USA. Hauptthemen laut MEDLINE: Hypercalcemia, Bone Density Conservation Agents, Parathyroid Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Endocrine Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Hypercalcemia is a common complication of malignancy that is associated with high morbidity and mortality.

Objective

To support development of the Endocrine Society Clinical Practice Guideline for the treatment of hypercalcemia of malignancy in adults.

Methods

We searched multiple databases for studies that addressed 8 clinical questions prioritized by a guideline panel from the Endocrine Society. Quantitative and qualitative synthesis was performed. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess certainty of evidence.

Results

We reviewed 1949 citations, from which we included 21 studies. The risk of bias for most of the included studies was moderate. A higher proportion of patients who received bisphosphonate achieved resolution of hypercalcemia when compared to placebo. The incidence rate of adverse events was significantly higher in the bisphosphonate group. Comparing denosumab to bisphosphonate, there was no significant difference in the rate of patients who achieved resolution of hypercalcemia. Two-thirds of patients with refractory/recurrent hypercalcemia of malignancy who received denosumab following bisphosphonate therapy achieved resolution of hypercalcemia. Addition of calcitonin to bisphosphonate therapy did not affect the resolution of hypercalcemia, time to normocalcemia, or hypocalcemia. Only indirect evidence was available to address questions on the management of hypercalcemia in tumors associated with high calcitriol levels, refractory/recurrent hypercalcemia of malignancy following the use of bisphosphonates, and the use of calcimimetics in the treatment of hypercalcemia associated with parathyroid carcinoma. The certainty of the evidence to address all 8 clinical questions was low to very low.

Conclusion

The evidence summarized in this systematic review addresses the benefits and harms of treatments of hypercalcemia of malignancy. Additional information about patients’ values and preferences, and other important decisional and contextual factors is needed to facilitate the development of clinical recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypercalcemiaBone Density Conservation AgentsParathyroid NeoplasmsHumansAdultDenosumabDiphosphonates

Stichwörter der Autor:innen

Endocrine Societybisphosphonatedenosumabhypercalcemia of malignancyskeletal-related events

Substanzen

DenosumabBone Density Conservation AgentsDiphosphonates

Autor:innen und Institutionen

  • Mayo Clinic Evidence-Based Practice Center, Rochester, MN 55902, USA.
  • Mayo Clinic Libraries, Rochester, MN 55902, USA.
  • Calcium Metabolism and Osteoporosis Program, American University of Beirut, Beirut, Lebanon.
  • Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic, Rochester, MN 55902, USA.

ORCID-Profile: Mohamed O Seisa, Tarek Nayfeh, Matthew T Drake, Mohammad Hassan Murad

Förderung

  • Endocrine Society

Zitieren

APA

Seisa, M. O., Nayfeh, T., Hasan, B., Firwana, M., Saadi, S., Mushannen, A., Shah, S. H., Rajjoub, N. S., Farah, M. H., Prokop, L. J., Wang, Z., Fuleihan, G. E., Drake, M. T., & Murad, M. H. (2023). A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults. The Journal of Clinical Endocrinology & Metabolism, 108(3), 585-591. https://doi.org/10.1210/clinem/dgac631

Vancouver

Seisa MO, Nayfeh T, Hasan B, Firwana M, Saadi S, Mushannen A, et al. A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults. The Journal of Clinical Endocrinology & Metabolism. 2023;108(3):585-591. doi:10.1210/clinem/dgac631

BibTeX
@article{Seisa2023,
  author = {Seisa, Mohamed O and Nayfeh, Tarek and Hasan, Bashar and Firwana, Mohammed and Saadi, Samer and Mushannen, Ahmed and Shah, Sahrish H and Rajjoub, Noora S and Farah, Magdoleen H and Prokop, Larry J and Wang, Zhen and Fuleihan, Ghada El-Hajj and Drake, Matthew T and Murad, Mohammad Hassan},
  title = {A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {108},
  number = {3},
  pages = {585--591},
  doi = {10.1210/clinem/dgac631}
}
Kostenlos starten →